CN100339080C - 抗病毒大环化合物 - Google Patents

抗病毒大环化合物 Download PDF

Info

Publication number
CN100339080C
CN100339080C CNB2005100094866A CN200510009486A CN100339080C CN 100339080 C CN100339080 C CN 100339080C CN B2005100094866 A CNB2005100094866 A CN B2005100094866A CN 200510009486 A CN200510009486 A CN 200510009486A CN 100339080 C CN100339080 C CN 100339080C
Authority
CN
China
Prior art keywords
methylene
nmr
phenylene
amd
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2005100094866A
Other languages
English (en)
Chinese (zh)
Other versions
CN1679562A (zh
Inventor
G·J·布里杰
E·M·伯林格
王忠仁
D·肖尔斯
R·T·斯基勒
D·E·博古茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arno Ahmed Co ltd
Genzyme Corp
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of CN1679562A publication Critical patent/CN1679562A/zh
Application granted granted Critical
Publication of CN100339080C publication Critical patent/CN100339080C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Structural Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB2005100094866A 1998-07-08 1999-07-08 抗病毒大环化合物 Expired - Lifetime CN100339080C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/111,895 US6506770B1 (en) 1996-06-06 1998-07-08 Antiviral compounds
US09/111,895 1998-07-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998082600A Division CN1195745C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Publications (2)

Publication Number Publication Date
CN1679562A CN1679562A (zh) 2005-10-12
CN100339080C true CN100339080C (zh) 2007-09-26

Family

ID=22341015

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100094866A Expired - Lifetime CN100339080C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物
CNB998082600A Expired - Fee Related CN1195745C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB998082600A Expired - Fee Related CN1195745C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Country Status (17)

Country Link
US (6) US6506770B1 (ko)
EP (1) EP1095031B1 (ko)
JP (1) JP4637353B2 (ko)
KR (1) KR100778134B1 (ko)
CN (2) CN100339080C (ko)
AP (1) AP1436A (ko)
AU (1) AU767359B2 (ko)
BR (1) BR9912524A (ko)
CA (1) CA2336634C (ko)
HU (1) HUP0102930A3 (ko)
IL (1) IL140605A0 (ko)
MX (1) MXPA01000137A (ko)
NO (1) NO20010047L (ko)
NZ (1) NZ509699A (ko)
PL (1) PL345516A1 (ko)
TR (1) TR200100030T2 (ko)
WO (1) WO2000002870A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438437A (zh) * 2015-04-02 2017-12-05 普罗克斯马根有限公司 用于癌症的新治疗
US10995091B2 (en) 2010-10-14 2021-05-04 Proximagen Llc CXCR4 receptor antagonists

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
EP1244648B1 (en) 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
SG126006A1 (en) * 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
US7052676B2 (en) * 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
WO2003011277A2 (en) * 2001-07-31 2003-02-13 Anormed Inc. Methods to mobilize progenitor/stem cells
KR20040068339A (ko) * 2001-12-21 2004-07-30 아노르메드 인코포레이티드 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
CA2521416A1 (en) 2003-04-02 2004-10-21 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
RU2005136224A (ru) 2003-04-22 2006-06-10 Анормед Инк. (Ca) Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
WO2005051927A1 (ja) * 2003-11-26 2005-06-09 Kureha Corporation Hiv-1感染末梢血単核球の刺激培養によるcd4陽性ｔ細胞の培養方法、及びhiv-1の増殖阻害剤
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
WO2007036036A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
BRPI0707446A2 (pt) 2006-02-02 2011-05-03 Allergan Inc composições e métodos para o tratamento de doença oftálmica
MX2008014296A (es) * 2006-06-12 2009-03-06 Pfizer Prod Inc Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
US20090274687A1 (en) * 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders
JP2012516354A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 乳癌を治療するための方法及び組成物
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012061662A1 (en) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103058998B (zh) * 2013-01-16 2016-04-13 山东鲁北药业有限公司 一种amd3465的制备工艺
EP3569609A1 (en) 2014-12-03 2019-11-20 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
US20180296551A1 (en) * 2015-10-19 2018-10-18 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating neurodegenerative diseases
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3009176A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
EP3471716A1 (en) * 2016-06-16 2019-04-24 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
KR102653723B1 (ko) 2016-10-07 2024-04-01 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
CN111683669A (zh) 2017-10-31 2020-09-18 美真达治疗公司 用于造血干细胞和祖细胞移植疗法的组合物和方法
WO2019089826A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
AU2018378804A1 (en) 2017-12-06 2020-06-11 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
JP2021510150A (ja) 2018-01-03 2021-04-15 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 造血幹細胞および前駆細胞の増幅ならびに遺伝性代謝障害の処置のための組成物および方法
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN115997009A (zh) 2020-04-27 2023-04-21 美真达治疗公司 用于在体内转导造血干细胞和祖细胞的方法和组合物
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583131A (en) * 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
EP0747368A1 (en) * 1995-06-06 1996-12-11 Johnson Matthey Public Limited Company Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents
US5698546A (en) * 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
EP1745797A3 (en) * 1998-03-24 2007-07-18 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
WO2005002522A2 (en) 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7315917B2 (en) * 2005-01-20 2008-01-01 Sandisk Corporation Scheduling of housekeeping operations in flash memory systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583131A (en) * 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
US5698546A (en) * 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines
EP0747368A1 (en) * 1995-06-06 1996-12-11 Johnson Matthey Public Limited Company Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995091B2 (en) 2010-10-14 2021-05-04 Proximagen Llc CXCR4 receptor antagonists
CN107438437A (zh) * 2015-04-02 2017-12-05 普罗克斯马根有限公司 用于癌症的新治疗
CN107438437B (zh) * 2015-04-02 2021-01-01 普罗克斯马根有限责任公司 用于癌症的治疗
US11311552B2 (en) 2015-04-02 2022-04-26 Proximagen, Llc Therapies for cancer

Also Published As

Publication number Publication date
WO2000002870A1 (en) 2000-01-20
MXPA01000137A (es) 2002-11-29
KR20010071764A (ko) 2001-07-31
JP2002520323A (ja) 2002-07-09
US20050154005A1 (en) 2005-07-14
US6872714B1 (en) 2005-03-29
CN1679562A (zh) 2005-10-12
US6756391B2 (en) 2004-06-29
NO20010047L (no) 2001-03-01
US7414065B2 (en) 2008-08-19
AU767359B2 (en) 2003-11-06
CN1308617A (zh) 2001-08-15
EP1095031B1 (en) 2013-08-21
US20030018189A1 (en) 2003-01-23
US7160872B2 (en) 2007-01-09
BR9912524A (pt) 2001-05-02
NO20010047D0 (no) 2001-01-04
CA2336634C (en) 2009-05-19
CN1195745C (zh) 2005-04-06
CA2336634A1 (en) 2000-01-20
IL140605A0 (en) 2002-02-10
US6506770B1 (en) 2003-01-14
AU4595999A (en) 2000-02-01
AP1436A (en) 2005-06-22
US20080287454A1 (en) 2008-11-20
US20040235814A1 (en) 2004-11-25
US7709486B2 (en) 2010-05-04
KR100778134B1 (ko) 2007-11-27
JP4637353B2 (ja) 2011-02-23
HUP0102930A3 (en) 2002-06-28
PL345516A1 (en) 2001-12-17
HUP0102930A2 (hu) 2001-11-28
AP2001002043A0 (en) 2001-03-31
NZ509699A (en) 2003-10-31
EP1095031A1 (en) 2001-05-02
TR200100030T2 (tr) 2001-06-21

Similar Documents

Publication Publication Date Title
CN100339080C (zh) 抗病毒大环化合物
CN1134420C (zh) 新的取代咪唑化合物
CN1138546C (zh) 用作细胞因子的某些1,4,5-三取代咪唑化合物
CN1305872C (zh) 喹唑啉类化合物的制备方法
CN1304375C (zh) 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
CN1213306A (zh) 新的取代咪唑化合物
CN1878759A (zh) 哒嗪－3(2h)－酮衍生物及其作为pde4抑制剂的用途
CN1213307A (zh) 新的取代的咪唑化合物
CN1636005A (zh) 苯并噻嗪酮和苯并噁嗪酮化合物
CN1694704A (zh) （1h－苯并咪唑－2－基）－（哌嗪基）－甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
CN1351590A (zh) 化合物
CN1262678A (zh) 三唑化合物及其作为多巴胺－d3－配体的应用
CN1882345A (zh) 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
CN1906188A (zh) 作为igf－1r抑制剂的苯基－[4－(3－苯基－1h－吡唑－4－基)－嘧啶－2－基]－胺衍生物
CN1886380A (zh) 苯并咪唑化合物
CN1333754A (zh) 苯并杂环和它们作为mek抑制剂的用途
CN1882571A (zh) 吡咯衍生物
CN1200120A (zh) 作为神经激肽拮抗剂的哌嗪子基衍生物
CN1478081A (zh) 取代的2-苯胺基苯并咪唑及其作为nhe抑制剂的用途
CN1113235A (zh) 苯并咪唑、含这些化合物的药物组合物和其制备方法
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1352644A (zh) 抑制磷酸二酯酶IV的1－氨基三唑并[4,3－α]喹唑啉－5酮类化合物和/或－5－硫酮类化合物
CN1694708A (zh) TGFβ的抑制剂
CN1714078A (zh) 可用于治疗雄激素受体相关疾病的吲哚类化合物
CN1413205A (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ANORMED LTD.

Free format text: FORMER OWNER: ANORMED INC.

Effective date: 20140326

Owner name: GENZYME CORP.

Free format text: FORMER OWNER: ANORMED LTD.

Effective date: 20140326

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140326

Address after: Massachusetts, USA

Patentee after: GENZYME Corp.

Address before: Nova Scotia Canada

Patentee before: Arno Ahmed Co.,Ltd.

Effective date of registration: 20140326

Address after: Nova Scotia Canada

Patentee after: Arno Ahmed Co.,Ltd.

Address before: British Columbia Canada

Patentee before: Anormed Inc.

CX01 Expiry of patent term

Granted publication date: 20070926

CX01 Expiry of patent term